Biomarkers for Diagnosing and Treating Fetal Growth Restriction-Reference-Cited by-同舟云学术

Biomarkers for Diagnosing and Treating Fetal Growth Restriction

Published:2023-10-25 Issue: Volume:31 Page:
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Wu Mengyao¹,He Junyu²,Chen Yetao¹,Wan Fangzhu¹,Tang Hongbo³,Yin Chenghong³,He Haibo¹⁴,Yu Huifan⁴,Yuan Chengfu²

Affiliation:

1. Hubei Key Laboratory of Natural Products Research and Development, Yichang Key Laboratory of Development and Utilization of Health Products with Drug and Food Homology, China Three Gorges University, Yichang443002, China

2. Basic Medical College of China Three Gorges University, Yichang443002, China

3. Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing100026, China

4. Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan 442000, China

Abstract

abstract: Fetal growth restriction (FGR), a common obstetric complication, significantly increases the risks of fetal intrauterine death and neonatal death, and fetuses with growth restriction are prone to cognitive retardation and various diseases in adulthood. The early determination of FGR risk is contentious in clinical research, and few indicators are available for the early prediction and diagnosis of FGR. This review focuses on the prediction and diagnosis of FGR, as well as the significance of biomarkers for FGR, such as those related to gene regulation, apoptosis, mitochondrial function, and inflammation. Although many of these biomarkers are still in the early stages of research, they are good predictors of the threats to fetal health and safety, and they provide new insights for the treatment of FGR.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry